Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies (part 2)
We report that previously described molecular subtypes of colorectal cancer are associated with the response to therapy in patients with metastatic disease. We also identified a patient population with high FOLFIRI sensitivity, as indicated by their 2.7-fold longer overall survival when treated with FOLFIRI, as first-line regimen, instead of FOLFOX. Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer.
Cancer Type: Colorectal Cancer
GPL: 570
Number of Genes with Data: 978
Number Observations: 56
Number Outputs: 4
Imbalanced Ratio: 0.866666667
Default Task: Classification